Interview with the CEO: Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Adrian “Ad” Rawcliffe has served as Chief Executive Officer of Adaptimmune Therapeutics PLC since September 2019 and is a member of the Executive Team. Previously, he served as the Chief Financial Officer from March 2015 through September 2019. Mr. Rawcliffe has over 20 years of experience within the biopharmaceutical industry and most recently served as Senior Vice President, Finance of GSK’s North American Pharmaceuticals business. He joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK’s Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK’s venture capital business. Mr. Rawcliffe currently serves as a non‑executive director of WAVE Life Sciences (NASDAQ:WVE). Mr. Rawcliffe qualified as a chartered accountant with PwC and holds a B.Sc. degree in Natural Sciences from the University of Durham, UK. Profile
Word count: 2,971
TWST: Let’s start with an overview of the company, its history and how it has evolved over the years.